Neuroendocrine Tumor Clinical Trials

• Signed informed consent form before any trial-related processes;

• Aged ≥ 18 years;

• Ki-67≥55% G3 NET and NEC were confirmed histologically or cytologically by pathological diagnosis in this study;

• Subjects failed first-line platinum-based chemotherapy;

• Adequate organ function;

• The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;

• Expected survival ≥ 12 weeks;

• Had at least one measurable tumor lesion according to RECIST v1.1;